Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid Tests Conclusively Diagnose Chagas Disease

By LabMedica International staff writers
Posted on 19 Apr 2017
Chagas disease is caused by infection with the Trypanosoma cruzi that are generally transmitted by triatomine vectors that are endemic to the Americas. It affects several million people and severe cardiac and/or digestive complications occur in about 30% of the chronically infected patients.

In recent decades, population movements from endemic to non-endemic regions and the chance of vector-independent transmission have globalized the disease impact to non-endemic countries like Spain. The acute stage of the disease is mostly asymptomatic and infection goes undiagnosed. In the chronic phase direct parasite detection is hampered due to its concealed presence and diagnosis is achieved by serological methods.

Scientists working with those at the Barcelona Institute for Global Health carried out a prospective study and took 342 blood samples from 223 women and 119 men living in an endemic region of Bolivia. Sampling was made between March and May 2014. The study was a double-blind with three different observers involved: two for each of the rapid diagnostic test (RDT), and a third one for the conventional serological tests (indirect hemagglutination assay (IHA), enzyme linked immunosorbent assays (ELISA), based on lysate antigen, and ELISA based on recombinant antigen.

The team used serodiagnosis, first by rapid screening with the RDT Chagas Stat-Pak. A second RDT, Chagas Detect Plus was also used in parallel. In order to qualify a rapidly diagnosed positive patient for treatment, conventional serological confirmation is obligatory. The ELISA tests were from Wiener Lab and included the parasite lysate-based ELISA.

The performance of CST and CDP was identical. The comparison with the conventional serology results yielded exactly the same results, either evaluating them individually or as a duo. Their reported sensitivity was 100% whereas specificity was 99.3%. RDTs positive predictive value was 99.5%, and their negative predictive value was 100%. In comparison with the three conventional serological tests, each RDT detected the same single false positive patient that was shown to be negative in all three conventional serology tests.

The authors concluded that their study validates the use of the CST and CDP diagnostic duo to reduce response time to patients and the logistic resources currently needed to elaborate a confirmed Chagas disease diagnosis. Therefore, they encourage considering the implementation of both RDTs with whole blood as sample to provide fast, reliable and definite diagnosis of Chagas disease in distant settings. The study was published on April 3, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.